Documente Academic
Documente Profesional
Documente Cultură
Hang T. Nguyen
29
Major Players
Industry Definition
29
DHG
Main Activities
30
TRA
Similar Industries
19
Competitive Landscape
31
IMP
Additional Resources
19
32
DMC
20
33
Sanofi
21
22
Basic of Competition
Industry at a Glance
18
Business Locations
Industry Performance
Executive Summary
Current Performance
24
Operating Conditions
12
Industry Outlook
24
13
24
25
Industry Assistance
25
Revenue Volatility
14
14
Supply Chain
14
26
Key Statistics
16
Demand Determinants
26
17
Major Markets
27
Glossary
Industry Update
Main Activities
Similar Industries
Additional Resources
www.vietinbanksc.com.vn
Industry at a Glance
Key Statistics 2013
Revenue
USD3.31bn
18.78%
Import
Export
15.51%
Businesses
8
6
15
2017f
2016f
2015f
2013
2014f
10
2012
TRA
2.37%
Growth (% y-o-y)
Source: BMI
Source: BMI
US$bn
%
25
20
2011
DHG
4.95%
Pharmceutical sales
2009
Sanofi
5.8%
US$bn
7
6
5
4
3
2
1
0
2010
Market share
185
Pharmaceutical trade
500
0
-500
-1000
-1500
-2000
-2500
-3000
-3500
-4000
-4500
0
-500
-1000
-1500
-2000
-2500
-3000
-3500
-4000
2009
2010
2011
2012
2013
2014f
2015f
2016f
2017f
Source: BMI
Industry Structure
www.vietinbanksc.com.vn
Life Cycle
Growth
Regulation Level
Revenue Volatility
Low
Technology Change
Capital Intensity
Low
Barriers to Entry
High
Medium
Low
Industry Assistance
Medium
Industry Globalization
Medium
Concentration Level
Medium
Low
Competition Level
Medium
High
Industry Performance
Executive Summary | Key External Drivers | Current Performance | Industry Outlook| Industry Life Cycle
Executive Summary
www.vietinbanksc.com.vn
Industry Performance
Executive Summary | Key External Drivers | Current Performance | Industry Outlook| Industry Life Cycle
Healthcare concerns
raise medicine costs
95
278
3,609
5,939
59
2,286
346
23
51
37
95
Source: Worldbank
US$bn
20
20
18.2
15
14.2
10
14
15
15
13.2
12.3
11
10
8.1
0
2009
2010
2011
2012
2013
2014f
2015f
2016f
2017f
Source: BMI
www.vietinbanksc.com.vn
Industry Performance
Executive Summary | Key External Drivers | Current Performance | Industry Outlook| Industry Life Cycle
90% pharmaceutical
materials used to produce
western medicines needs
to be imported.
US$mn
400
300
40%
200
20%
100
0%
-20%
2008 2009 2010 2011 2012 2013
Import values
Growth (%y-o-y)
Source: GSO
Price index of material used for industry
production (compared with the previous
year (%))
2010
2011
2012
Agriculture,
Forestry and
11.51
30.65
8.34
Fisherires
Food, beverage
10.38
22.75
8.47
and tobacco
Textile
5.8
13.82
14.31
Processed wood
15.55
25.58
9.89
and footwear
Chemicals
4.29
18.33
9.86
Medicinces and
6.51
9.94
8.57
pharmaceuticals
Rubber products,
non-metallic
6.61
16.36
13.8
minerals
Electrical
4.32
11.11
5.31
equipments
Transport
3.74
6.77
1.38
equipments
Industries
9.59
21.27
9.88
average
www.vietinbanksc.com.vn
China
1.21%
India
0.35%
Austria
4.95%
Spain
Germany
7.03%
France
57.27%
17.97%
Italia
Sweden
Korea
United Kingdom
Japan
Industry Performance
Executive Summary | Key External Drivers | Current Performance | Industry Outlook| Industry Life Cycle
Traditional pharmaceticals
Material source for traditional pharmaceutical industry is produced inhouse
rather than imported as western pharmaceuticals. With over 4,000 species
of herbs, Vietnam ranks the third worldwide in term of biological diversity.
Furthermore, the usage rate of traditional pharmaceuticals is increasing,
and according to Ministry of Healths forecast, this rate will increase to 30%
in the next 5 years. Therefore, traditional pharmaceutical is a highly
potential sub-sector which reduces the reliance on import of pharmaceutical
industry in general.
Loose price management and intellectual property protection
Price management and intellectual property protection of the government
have not been implemented closely, thus the price of this product still
increases over the years on average, and the status of counterfeit
medicines still remains.
www.vietinbanksc.com.vn
Industry Performance
Executive Summary | Key External Drivers | Current Performance | Industry Outlook| Industry Life Cycle
Current performance
Source: BMI
2009
0
2017f
0
2016f
10
2015f
20
2013
10
Source: BMI
Source: BMI
2009
2010
2011
2012
2013
2014f
2015f
2016f
2017f
2017f
2016f
2015f
2013
2014f
2012
2011
2010
2009
20
30
2014f
50,000
30
2012
100,000
40
2011
150,000
2.3
2.2
2.1
2
1.9
1.8
1.7
1.6
2010
Revenue/GDP (%)
Profitability
25%
ROA %
30
25
20%
20
15%
15
10%
10
DHG
DMC
5%
SPM
0%
2009 2010 2011 2012 2013
Gross profit margin
EBIT margin
Net profit margin
Source: VietinbankSc
www.vietinbanksc.com.vn
VMD
-5
-10
0
1000
2000
3000
4000
5000
6000
Source: VietinbankSc
Industry Performance
Executive Summary | Key External Drivers | Current Performance | Industry Outlook| Industry Life Cycle
0
-500
-1000
-1500
-2000
-2500
-3000
-3500
-4000
0
-1000
-2000
-3000
-4000
-5000
2009
2010
2011
2012
2013
2014f
2015f
2016f
2017f
Source: BMI
France
India
Korea
Germany
14.49%
Switzerland
23.17%
Italia
12.98%
2.32%
United Kingdom
Belgium
2.41%
8.34%
3.21%
3.28%
Ireland
Thailand
USA
3.62%
China
7.97%
3.83%
4.20%
4.93% 5.25%
Australia
Others
www.vietinbanksc.com.vn
Industry Performance
Executive Summary | Key External Drivers | Current Performance | Industry Outlook| Industry Life Cycle
Pharmaceuticals are
imported maily from
France, India and Korea
Vietnam imports pharmaceuticals mainly from France, India and Kroea. The
advantage of French market is that medicine line is stable and that
medicines are seldom counterfeited. Although the price of medicines
imported from France is higher than that of domestic products, French
medicines are still more rational compared with other markets. Regarding
Indian market, due to cheap labor and plentiful raw material sources, Indian
pharmaceuticals are competive in term of price.
Export is weak
Export price of
Vietnamese
pharmaceuticals is 2030% higher India and
China.
Export grew at a rate of
25.93% per annum
during the period of 0913.
Forecast: Growth rate
will stay the same during
the period of 14-18
The pharmaceutical export of Vietnam still faces the barriers of prices and
export policies.
Firstly, according to Price Management Department, the annual average
export price of Vietnam is 20%-25% higher than other countries in the
region such as India and China. If the domestic prices are reduced equal to
the prices of those countries, domestic companies will no longer make profit
to stay in business. The high price is caused by the fact that Vietnam
pharmaceutical industry has to import main materials while those two
countries can manage this matter in-house. Secondly, product registration
process still faces many difficulties of time consuming. In order to bring
products to new markets, companies must send registration form,
application form and product sample for testing. This process takes up to 2
years.
However, export performance is gradually becoming better as export
revenues have increased over the years. For example, the export revenue
of DHG increased from several thousand USD in 2006 to over one million
USD in 2012, taking up 2% of the industrys export turnover. Domesco
experiences an increase in revenue from 1.2% in 2009 to nearly 1.5% in
2012.
By 2013, Vietnamese companies has exported to countries including
Myanma, Lao, Cambodia, India, Hongkong, Philippin, Malaysia, and more
than 20 countries in Africa. BMI forecasts that export continues to grow
rapidly and reaches USD250 million in 2017. This is based on the
assessment of some potential markets in Africa since 70% of demand in
African countries can only be met by import, as WHO said. Primary
products needed including medicines for malaria and diarrhea and vaccines
are those products that Vietnamese companies can produce.
Financial performance: Liquidity and leverage
1.8
1.7
1.6
1.5
1.4
1.3
1.2
1.1
1.0
Debt/Eqity
Source: VietinbankSc
www.vietinbanksc.com.vn
10
Industry Performance
Executive Summary | Key External Drivers | Current Performance | Industry Outlook| Industry Life Cycle
IndustryLiquidity
2.50
2.00
1.50
1.00
0.50
0.00
Current ratio
by
joint
provincial
circular
No
Source: VietinbankSc
Pharmaceutical prices
and the CPI increase in
the same direction.
Prices of imported
pharmaceuticals increase
more than that of
domestic ones.
Priceindexvolatilityof
Pharmaceuticalproducts
andUSD
%
16.3
13.8
13.2
8.9
5.44.95.1
2.9
6.1
5.7
3.4
2000
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
18
16
14
12
10
8
6
4
2
0
Source: GSO
www.vietinbanksc.com.vn
11
Industry Performance
Executive Summary | Key External Drivers | Current Performance | Industry Outlook| Industry Life Cycle
The pharmaceutical industry is forecasted to continue to grow in the next 5
years. Low pharmaceutical expenditure per capita (31.6 USD), together
with population explosion and the increasing awareness about healthcare
will create strong premise for purchasing power of pharmaceuticals, leading
to the growth of the industry.
Industry outlook
Continue to grow at an
average rate of 14.7%
per annum during the
period of 14-18
$US
50
40
30
20
10
2017f
2016f
2015f
2013
2014f
2012
2011
2010
2009
Source: BMI
US$m
7
Sales values of
prescription and OTC
drugs
6
5
4
3
2
1
0
Source: BMI
USDmn
Revenues of patented
medicines & of generic
medicines
4
3
2
1
2017f
2016f
2015f
2014f
2013
2012
2011
2010
2009
Source: BMI
www.vietinbanksc.com.vn
12
Industry Performance
Executive Summary | Key External Drivers | Current Performance | Industry Outlook| Industry Life Cycle
Industry life cycle
The pharmaceutical
industry is still in the
early stage of GROWTH
period.
35
Venezuela
30
25
Vietnam
20
China
15
10
Germany
USA
0
-5
0
100
200
300
400
Revenue 2012 (US$bn)
500
600
www.vietinbanksc.com.vn
13
Supply Chain
The revenue of
traditional medicines
contributes from 0.5% to
1.5% to total revenues.
www.vietinbanksc.com.vn
In term of disease
Revenues obtained from nutrition pharmaceuticals and systemic infection
pharmaceuticals are the highest, followed by cardiovascular and nerve.
14
Busine
-sses
No of
products
Impo
-rted
Produced
2009
1,114
1,861
832
1,029
2010
1,626
3,721
2011
1,512
3560
2012
1,552
5,514
1,63
2
1,83
6
3,19
8
2,089
1,724
2,316
Source: Vaff
17%
3%
20%
3%
12%
19%
9%
16%
Systemic infection
Respiratory
Musculoskeletal
Others
www.vietinbanksc.com.vn
15
Vietnams pharmaceutical
industry mainly serves the
domestic market, in which
the sale channels through
medical facilities account
for over 70% of revenue.
www.vietinbanksc.com.vn
16
Vietnam pharmaceutical
industry concentrates on
domestic market.
Especially, revenues
generated from medical
facilities account for 70%.
Marketssegmentation
26.50
%
3.02%
OTC
Medical facilities
More than 70% of medicine revenues in Vietnam come from hospitals
(including the direct use of medicines in hospitals and from prescription by
doctors). The fact the number of medical facilities has increased over the
years and that people have a habit of seeing doctors facilitate the growth of
the industrys revenue in this segment.
When separately calculating in terms of domestic medicines, this figure is
less than 50%. Besides, the usage rate of domestic medicines in hospitals
is different when the usage rate of domestic medicines in the central
hospitals is 12% while that figure of provincial hospitals and district health
stations are 34% and 60% respectively.
Additionally, the usage rate of domestic medicines in hospitals is likely to
decrease due to the effect of Circular 01 as medicines of cheap prices win
the bid. And it is more likely that most medicines of cheap prices are those
importd from China and India.
70.48
%
Medical facilities
Exports
Source: VietinbankSc
43
44
59
62
10,979
11,028
11,047
10,757
710
710
710
715
34
33
30
34
41849
42000
N/A
57000
Retail drugstores
The number of drugs sold in drugstores in Vietnam is quite high (50-60%).
However, since medicines sold in drugstores are common medicines and
tonic with lower prices than specific medicines prescribed through hospitals,
then in terms of revenue, medicines at drugstores take up only 26.5% of
market share. In 2012, there were about 57,000 drugstores in the country,
which means that every 10,000 people, there were 6.3 drugstores.
Export
Export of Vietnam pharmaceutical products is still low. The trade balance of
pharmaceutical industry remains negative in the past years. Nevertheless,
the government still provides favorable conditions to encourage Vietnamese
enterprises to export to international markets. Those conditions include
urging enterprises to meet GMP standards, supporting investment projects,
reducing import tax of raw material to 0%.
Following the same strategy of neighboring countries such as Bangladesh,
Pakistan, Vietnam pharmaceutical industry targets exporting to markets that
have low barriers to entry. The Southeast Asian countries such as Laos
and Cambodia are primary markets, while African region and the Middle
East will eventually be noticed.
www.vietinbanksc.com.vn
17
Business location
Source: VietinbankSc
www.vietinbanksc.com.vn
18
Brokerage Department - HO
T +84 4 3974 6900
F +84 4 3974 7572
E moigioichungkhoan@vietinbanksc.com.vn
Brokerage Department HCM Branch
T +84 8 3820 9987
F +84 8 3820 0921
E moigioiHCM@vietinbanksc.com.vn
W www.vietinbanksc.com.vn
www.vietinbanksc.com.vn
Disclaimer
This report has been provided by Vietinbank Securities
JSC (VietinbankSC) solely for use by its clients, strictly in
accordance with VietinbankSCs terms of use.
VietinbankSC makes no representation to any other
person with regard to the completeness or accuracy of
the data or information contained herein, and it accepts
no responsibility and disclaims all liability (save for liability
which cannot be lawfully disclaimed) for loss or damage
whatsoever suffered or incurred by any other person